Increasing genetic or chromosomal abnormality is expected to drive the global pulmonary atresia diagnostics and treatment market during the forecast period

Pune, India, 2022 /MRFR Press Release/- Market Research Future published a half-cooked research report on the global pulmonary atresia diagnostics and treatment market.

Pulmonary Atresia Diagnostics and Treatment Market Highlights

A pulmonary atresia is a form of birth disease where the pulmonary valve which controls the flow of blood from the right ventricle to the pulmonary artery does not work effectively. In some cases, babies with pulmonary atresia may also have a small or missing, right ventricle that cannot properly pump blood to the lungs. In the case of pulmonary atresia, there is no threat to life, while the fetus is developing because the placenta is used to provide oxygen to the baby when the lungs are not functioning. Only after birth, the symptoms are noted and if the newborn baby turns blue or grey in color when the maternal source of oxygen is detached, it indicates that the newborn is suffering from the disease.

The Pulmonary Atresia Diagnostics and Treatment Market is expected to reach USD 4.89 Billion by 2030 at 5.10% CAGR during the forecast period 2023-2030.

However, unspecified regulatory issues, infection risks connected with surgical procedures, and ambiguous reimbursement policies are the factors limiting the market growth.

Segmentation

The global pulmonary atresia diagnostics and treatment market has been segmented on the basis of type, diagnosis, treatment and end users.

On the basis of type, the market has been classified as pulmonary atresia with an intact ventricular septum and pulmonary atresia with ventricular septum defect. On the basis of diagnosis, the market has been classified as pulse oximetry, electrocardiogram (ECG), echocardiogram (cardiac ultrasound), cardiac MRI and cardiac catheterization. On the basis of treatment, the market has been classified as medication, cardiac catheterization, surgery. The cardiac catheterization is segmented into radiofrequency ablation and balloon valvotomy, balloon atrial septostomy, and stent placement. The surgery is segmented into right ventricular outflow reconstruction, blalock-taussig shunt, bi-directional glenn procedure, fontan procedure, and heart transplant. On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, research institutes, and others.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Pulmonary Atresia Diagnostics and Treatment Market Research Report

Regional Analysis

The Americas is projected to lead the pulmonary atresia diagnostics and treatment market in the forecast period. Increasing healthcare awareness, advancement in technology, medical tourism are some other factors that boost the growth of the market. According to the Centers for Disease Control and Prevention of US, the Congenital Heart Disease affects nearly 1% of births per year in the US and nearly 25% of babies are having critical Congenital Heart Disease.

The European market is expected to hold the second largest market share. The frequency of chromosomal irregularities was 3.6 per 1,000 births in Europe. The market is expected to witness growth owing to the rising patient population, changing lifestyle, and growing elderly population. This is expected to provide favorable backgrounds for the market to grow.

Asia-Pacific is projected to be the fastest growing region for the global pulmonary atresia diagnostics and treatment market in 2018. The diagnostic testing market, by volume, in India is controlled by microscopy testing. With increasing awareness and growing funding from care-based surveillance systems, private sectors and national governments the necessity for diagnostic testing procedures are projected to rise, thereby boosting the market development.

The Middle East and Africa accounts for the least share due to stringent government policies and low per capita income.

Key Players

Some of the key players in the global pulmonary atresia diagnostics and treatment market are Kyowa Pharma Chemical Co. Ltd, AZAD partners, Abbott Laboratories, Dickinson and Company, Becton, C. R. Bard, Inc., B. Braun Melsungen AG, Medtronic plc., Teleflex Incorporated, JOHNSON & JOHNSON, Cook Group Incorporated, and Boston Scientific Corporation.